UMRX - Unum Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.3900
+0.1900 (+8.64%)
At close: 4:00PM EDT

2.3700 -0.02 (-0.84%)
Before hours: 7:31AM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Bollinger Bands

Bollinger Bands

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.2000
Open2.5200
Bid2.3200 x 2200
Ask2.4000 x 900
Day's Range2.1800 - 3.3900
52 Week Range0.2950 - 3.4000
Volume42,554,882
Avg. Volume2,336,579
Market Cap74.477M
Beta (5Y Monthly)1.31
PE Ratio (TTM)N/A
EPS (TTM)-0.8600
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
    PR Newswire

    Unum Therapeutics Inc. Announces Acquisition of Kiq LLC

    Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biopharmaceutical company focused on developing therapies for solid tumors, today announced it has completed the acquisition of Kiq LLC ("Kiq"), a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors. Concurrent with the acquisition of Kiq, Unum entered into a definitive agreement for the sale of Series A non-voting convertible Preferred Stock (the "Series A Preferred Stock") in a private placement to a group of institutional accredited investors led by Fairmount Funds Management LLC ("Fairmount Funds"), with participation from Venrock Healthcare Capital Partners, BVF Partners L.P., Atlas Venture, Acorn Bioventures, Perceptive Advisor's LLC, RTW Investments, OrbiMed, Samsara BioCapital, Logos Capital, Ally Bridge Group and Commodore Capital, as well as additional undisclosed institutional investors. The private placement is expected to result in gross proceeds to Unum of approximately $104.4 million before deducting placement agent and other offering expenses. The proceeds from the private placement will be used to advance clinical testing of PLX9486, a highly potent and selective KIT D816V inhibitor, in multiple indications and provide runway beyond 2022.

  • GlobeNewswire

    INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Unum Therapeutics Inc. for Potential Breach of Fiduciary Duty Claims

    NEW YORK, June 15, 2020 -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Unum Therapeutics Inc..

  • Is Unum Therapeutics Inc. (UMRX) A Good Stock To Buy?
    Insider Monkey

    Is Unum Therapeutics Inc. (UMRX) A Good Stock To Buy?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]

  • Unum Therapeutics Inc (UMRX) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Unum Therapeutics Inc (UMRX) Reports Q1 Loss, Tops Revenue Estimates

    Unum Therapeutics Inc (UMRX) delivered earnings and revenue surprises of 39.39% and 134.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates

    Unum Therapeutics Inc. (UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the first quarter ended March 31, 2020, and provided corporate updates. Announced plans to prioritize resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers: On March 2nd, Unum announced a corporate restructuring plan to prioritize resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers. Unum’s BOXR1030 expresses a glypican-3 (GPC3) targeted CAR and incorporates the novel transgene glutamic-oxaloacetic transaminase 2 (GOT2) to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism.

  • GlobeNewswire

    Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates

    CAMBRIDGE, Mass., March 26, 2020 -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today.

  • GlobeNewswire

    Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital

    Unum Therapeutics Inc. (UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced it has entered into a common stock purchase agreement for up to $25 million with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor. Under the terms of the purchase agreement, Unum Therapeutics will have the sole discretion, but not the obligation, to direct LPC to purchase up to $25 million in shares of its common stock over the 36-month term of the agreement.

  • GlobeNewswire

    Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers

    Unum Therapeutics Inc. (UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced plans to prioritize resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers. Unum’s BOXR1030 expresses a glypican-3 (GPC3) targeted CAR and incorporates the novel transgene glutamic-oxaloacetic transaminase 2 (GOT2) to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism.

  • GlobeNewswire

    Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers

    Unum Therapeutics Inc. (UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced it has completed Cohort 1 enrollment with no dose-limiting toxiticies (DLT) observed in the ATTCK-34-01 Phase 1 trial evaluating Unum’s novel Antibody-Coupled T cell Receptor investigational therapy, ACTR707, together with trastuzumab for the treatment of patients with HER2+ advanced cancers. Patient enrollment—defined as patients who have signed informed consent forms and met all eligibility criteria—is complete with five patients in this first cohort in the ATTCK-34-01 Phase 1 trial, a multicenter, open-label, single-arm, dose-escalation trial.

  • Did Changing Sentiment Drive Unum Therapeutics's (NASDAQ:UMRX) Share Price Down A Painful 77%?
    Simply Wall St.

    Did Changing Sentiment Drive Unum Therapeutics's (NASDAQ:UMRX) Share Price Down A Painful 77%?

    Unum Therapeutics Inc. (NASDAQ:UMRX) shareholders will doubtless be very grateful to see the share price up 53% in the...

  • Hedge Funds Are Selling Unum Therapeutics Inc. (UMRX)
    Insider Monkey

    Hedge Funds Are Selling Unum Therapeutics Inc. (UMRX)

    Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]

  • GlobeNewswire

    Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting

    CAMBRIDGE, Mass., Dec. 07, 2019 -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer,.

  • GlobeNewswire

    Unum Therapeutics to Present at Upcoming Investor Conference

    CAMBRIDGE, Mass., Nov. 15, 2019 -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer,.

  • Unum Therapeutics Inc. (UMRX) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Unum Therapeutics Inc. (UMRX) Reports Q3 Loss, Misses Revenue Estimates

    Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of -25.81% and -76.87%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Unum Therapeutics Reports Third Quarter 2019 Financial Results

    - Progress towards focusing on solid tumors remains on track with enrollment and early safety updates from Phase 1 trial of ACTR707 in HER2+ cancers expected by the end of this.

  • GlobeNewswire

    Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    “Solid tumors create an unfavorable microenvironment that depletes T cells of critical nutrients and amino acids, drives T cell dysfunction, and inhibits the effectiveness of cellular therapies, and our BOXR platform was specifically developed to discover novel transgenes that can be co-expressed with chimeric-targeting receptors to improve T cell functionality in the solid tumor microenvironment,” said Seth Ettenberg, Ph.D., Chief Scientific Officer of Unum. “At this year’s SITC, we present preclinical data on the first product candidate from our BOXR platform, BOXR1030, which contains the GOT2 transgene.

  • GlobeNewswire

    Unum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers

    Unum Therapeutics Inc. (UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced a strategic shift to focus development on its ACTR and BOXR product candidates in solid tumors and supportive platform capabilities. “We are uniquely positioned to address the challenge of treating solid tumor cancers, and now is the time to focus our efforts, having recently validated our ACTR technology in the hematologic setting and with preclinical data emerging from BOXR1030, the first product candidate from our BOXR platform.

  • Unum Therapeutics Inc. (UMRX) Expected to Beat Earnings Estimates: Should You Buy?
    Zacks

    Unum Therapeutics Inc. (UMRX) Expected to Beat Earnings Estimates: Should You Buy?

    Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Here's Why We're Watching Unum Therapeutics's (NASDAQ:UMRX) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Watching Unum Therapeutics's (NASDAQ:UMRX) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • GlobeNewswire

    Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting

    CAMBRIDGE, Mass., Oct. 02, 2019 -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer,.

  • GlobeNewswire

    Unum Therapeutics to Present at Upcoming September Investor Conferences

    CAMBRIDGE, Mass., Aug. 26, 2019 -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer,.

  • Thomson Reuters StreetEvents

    Edited Transcript of UMRX earnings conference call or presentation 12-Aug-19 8:30pm GMT

    Q2 2019 Unum Therapeutics Inc Earnings Call

  • Unum Therapeutics Inc. (UMRX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Unum Therapeutics Inc. (UMRX) Reports Q2 Loss, Tops Revenue Estimates

    Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 12.82% and 1.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Unum Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Updates

    - Updated results from Phase 1 trial with ACTR707 in combination with rituximab in adults with relapsed/refractory non-Hodgkin lymphoma confirms the clinical activity achieved.

  • ACCESSWIRE

    Unum Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 12, 2019 / Unum Therapeutics, Inc. (NASDAQ: UMRX ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 at 4:30 ...